Evotaz FDA Approval History

Last updated by Judith Stewart, BPharm on Jan 28, 2021.

FDA Approved: Yes (First approved January 29, 2015)
Brand name: Evotaz
Generic name: atazanavir and cobicistat
Dosage form: Tablets
Company: Bristol-Myers Squibb Company
Treatment for: HIV Infection

Evotaz (atazanavir and cobicistat) is a two-drug combination of atazanavir, a human immunodeficiency virus (HIV-1) protease inhibitor, and cobicistat, a CYP3A inhibitor indicated for use in combination with other antiretroviral agents for the treatment of HIV-1infection in adults and pediatric patients weighing at least 35 kg.

Development timeline for Evotaz

Date	Article
Jan 29, 2015	Approval FDA Approves Evotaz (atazanavir and cobicistat) for HIV-1 Infection in Adults
Apr 14, 2014	Bristol-Myers Squibb Submits NDA to FDA for Fixed-Dose Combination of Atazanavir Sulfate with Cobicistat

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer